SWOG S0925: A randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer

Evan Y. Yu, Hongli Li, Celestia S. Higano, Neeraj Agarwal, Sumanta K. Pal, Ajjai Alva, Elisabeth I. Heath, Elaine T. Lam, Shilpa Gupta, Michael B. Lilly, Yoshio Inoue, Kim N. Chi, Nicholas J. Vogelzang, David I. Quinn, Heather H. Cheng, Stephen R. Plymate, Maha Hussain, Catherine M. Tangen, Ian M. Thompson

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

Purpose: Cixutumumab, formerly IMC-A12, is a recombinant human monoclonal immunoglobulin G1antibody that targets insulin-like growth factor I receptor (IGF-IR). Cixutumumab was synergistic with castration in a hormone-sensitive prostate cancer xenograft model. Patients and Methods: Patients with new metastatic prostate cancer were randomly assigned within 30 days of initiating androgen deprivation (AD) to cixutumumab added to a luteinizing hormone-releasing hormone agonist with bicalutamide versus AD alone. With 180 patients and one-sided alpha of 0.10, there would be 90% power to detect an absolute 20% difference in undetectable prostate-specific antigen (PSA; ≤ 0.2 ng/mL) rate at 28 weeks (relative risk, 1.44); this end point was previously strongly correlated with survival. Secondary end points included the proportion of patients with PSA > 4.0 ng/mL, safety and tolerability, circulating tumor cell (CTC) levels, and seven plasma IGF-IR biomarkers. Fisher's exact test was used for the primary end point, and extended Mantel-Haenszel χ2 test was used for three PSA response categories. Results: The trial accrued 210 eligible patients (105 randomly assigned to each arm). Patient characteristics were similar in both arms. Undetectable PSA rate was 42 (40.0%) of 105 for cixutumumab plus AD and 34 (32.3%) of 105 for AD alone (relative risk, 1.24; one-sided P = .16). Lower baseline CTCs (0 v 1 to 4 v ≥ 5/7.5 mL whole blood) were associated with higher rate of PSA response (three categories; P = .036) in 39 evaluable patients. IGF-IR biomarkers were not correlated with PSA outcome, and cixutumumab did not significantly change these biomarker levels. Conclusion: Cixutumumab plus AD did not significantly increase the undetectable PSA rate in men with new metastatic hormone-sensitive prostate cancer. CTCs at baseline may carry prognostic value.

Original languageEnglish (US)
Pages (from-to)1601-1608
Number of pages8
JournalJournal of Clinical Oncology
Volume33
Issue number14
DOIs
StatePublished - May 10 2015

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'SWOG S0925: A randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer'. Together they form a unique fingerprint.

  • Cite this

    Yu, E. Y., Li, H., Higano, C. S., Agarwal, N., Pal, S. K., Alva, A., Heath, E. I., Lam, E. T., Gupta, S., Lilly, M. B., Inoue, Y., Chi, K. N., Vogelzang, N. J., Quinn, D. I., Cheng, H. H., Plymate, S. R., Hussain, M., Tangen, C. M., & Thompson, I. M. (2015). SWOG S0925: A randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer. Journal of Clinical Oncology, 33(14), 1601-1608. https://doi.org/10.1200/JCO.2014.59.4127